The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Viraj Shah
No Relationships to Disclose
 
Harikrishnan Hyma Kunhiraman
No Relationships to Disclose
 
Tarek Nahle
Employment - Regeneron (I)
 
Omar Elsayed
No Relationships to Disclose
 
Nickolas Stabellini
No Relationships to Disclose
 
Priyanshu Nain
No Relationships to Disclose
 
Aditya Bhave
No Relationships to Disclose
 
Sathvika Narasimhan
No Relationships to Disclose
 
Sai Suraj Kollapaneni
No Relationships to Disclose
 
Lakshya Seth
No Relationships to Disclose
 
Biplab Datta
No Relationships to Disclose
 
Justin Moore
No Relationships to Disclose
 
Jennifer Cullen
Patents, Royalties, Other Intellectual Property - 1. Patent #: US-20210080466-A1 Publication number: 20210080466 Title: MARKERS FOR THE DIAGNOSIS OF BIOCHEMICAL RECURRENCE IN PROSTATE CANCER Type: Application Filed: June 26, 2020 Publication date: March 18, 2021; Provisional Patent Application No. 62/888,890 ; Title: PROTEIN PANELS FOR THE EARLY DIAGNOSIS/PROGNOSIS OF AGGRESSIVE PROSTATE CANCER; Filed on August 19, 2019
 
Neal Weintraub
No Relationships to Disclose
 
Sourbha Dani
No Relationships to Disclose
 
Sarju Ganatra
No Relationships to Disclose
 
Umang Swami
Consulting or Advisory Role - Adaptimmune; Astellas Pharma; AstraZeneca; Exelixis; Flatiron Health; Gilead Sciences; Janssen Scientific Affairs; Kairos Therapeutics; Pfizer
Research Funding - Exelixis (Inst); Janssen (Inst); lava therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst)
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Avirup Guha
Employment - AstraZeneca (I)
Consulting or Advisory Role - Myovant Sciences; Novartis; Pfizer
Research Funding - Sumitovant Biopharma (Inst)